Men’s Health | Erectile Dysfunction

F-ESWT for Erectile Dysfunction:
The Science-Backed Shockwave Treatment That Restores Function Without Pills or Surgery

More than 1 in 4 American men live with erectile dysfunction — yet fewer than 1 in 13 ever discuss it with a doctor. A breakthrough non-invasive treatment is changing that conversation.

What Is Erectile Dysfunction — And Why Is It So Undertreated?

Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection firm enough for satisfying sexual activity. According to the 2021 National Survey of Sexual Wellbeing — with results published in 2024 — approximately 24.2% of men in the United States experience ED. That’s roughly 1 in 4.

Yet only 7.7% of men with ED have received a formal diagnosis from a healthcare provider. The gap is staggering: millions of men are silently managing a condition that has effective, evidence-based treatments available — including a non-invasive option that most of them have never heard of.

ED prevalence increases with age, but it is far from exclusively an older man’s problem:

• 18–24 years: 17.9%
• 25–34 years: 13.3%
• 35–44 years: 12.7%
• 45–54 years: 25.3%
• 55–64 years: 33.9%
• 65–74 years: 48.0%
• 75+ years: 52.2%

Even in the youngest age bracket surveyed, nearly 1 in 5 men report difficulty. This is not a niche problem. It is one of the most common — and most under-discussed — men’s health conditions in the country.

The Root Cause Most Men Don’t Know About: Vascular Insufficiency

ED has multiple contributing causes — hormonal imbalance, neurological factors, psychological stress, and medication side effects can all play a role. But for the majority of men, particularly those over 40, the primary driver is vasculogenic: compromised blood flow to penile tissue.

An erection is a vascular event. It depends on the rapid, coordinated dilation of penile arteries and the filling of the corpus cavernosum with blood. When the arterial supply is compromised — by atherosclerosis, endothelial dysfunction, hypertension, diabetes, or simply the cumulative effects of aging — the hydraulic pressure needed for a firm erection cannot be achieved or sustained.

This is why ED is now widely recognized as an early warning sign of cardiovascular disease. The penile arteries, at roughly 1–2mm in diameter, are smaller than the coronary arteries that supply the heart. They show signs of vascular disease earlier — meaning ED can precede a cardiac event by 3–5 years in some patients.

Understanding that ED is fundamentally a vascular problem is key to understanding why F-ESWT works so well.

What Is F-ESWT?

F-ESWT stands for Focused Extracorporeal Shockwave Therapy. “Extracorporeal” means the energy is delivered from outside the body — no needles, no incisions, no anesthesia. A handheld device is applied to the penis and delivers precisely targeted acoustic pressure waves (shockwaves) deep into penile tissue.

The “focused” distinction is important. Unlike radial shockwave therapy, which disperses energy in a wide cone, focused shockwave therapy concentrates acoustic energy at a specific tissue depth — allowing clinicians to target the cavernous arteries and erectile tissue directly with far greater precision and penetration.

Shockwave therapy has been used in orthopedics for decades to treat tendinopathy, calcific shoulder conditions, and chronic wound healing. Its application to ED is newer but growing rapidly, with a robust and expanding body of randomized controlled trial evidence behind it.

How F-ESWT Works: The Biology of Restoration

The mechanism by which F-ESWT reverses vasculogenic ED is well-characterized. The acoustic pressure waves trigger a cascade of biological repair processes through a phenomenon called mechanotransduction — the conversion of mechanical force into cellular biological signals.

Here’s what happens at the cellular level:

1. Shockwaves activate endothelial cells lining the walls of penile blood vessels. This mechanical stimulation signals the cells to upregulate production of key growth factors.

2. VEGF (Vascular Endothelial Growth Factor) is released. VEGF is the body’s primary signal for new blood vessel formation. Elevated VEGF expression triggers the sprouting of new capillary networks — a process called neovascularization.

3. eNOS (endothelial Nitric Oxide Synthase) is upregulated. eNOS produces nitric oxide (NO), the molecular signal responsible for smooth muscle relaxation and arterial dilation during erection. Men with vasculogenic ED characteristically have reduced NO bioavailability — F-ESWT directly addresses this deficit.

4. PCNA (Proliferating Cell Nuclear Antigen) is activated, promoting the proliferation of progenitor cells that form the scaffolding for new blood vessel growth.

5. Neovascularization occurs over weeks to months. New microvascular networks develop within penile tissue, restoring the blood flow dynamics required for normal erectile function.

The result is not a temporary pharmacological effect — it is structural tissue repair. Unlike PDE5 inhibitors (Viagra, Cialis), which work by preventing the breakdown of cGMP to facilitate blood flow only when taken, F-ESWT addresses the underlying arterial deficit. For men who are good candidates, the improvement can be durable.

What Does the Clinical Evidence Show?

The evidence base for F-ESWT in vasculogenic ED has grown substantially over the past decade, and the 2025 literature now includes high-quality meta-analytic data.

A 2025 meta-analysis of 12 randomized controlled trials enrolling 882 men with vasculogenic ED found statistically significant improvements in International Index of Erectile Function — Erectile Function domain (IIEF-EF) scores at the 6-month follow-up mark compared to sham/control groups. The IIEF-EF is the gold-standard patient-reported outcome measure for erectile function in clinical research.

Key findings from the meta-analytic literature include:

• Statistically significant IIEF-EF improvement vs. sham at 6 months post-treatment
• Greatest benefit in men with mild-to-moderate vasculogenic ED — the population with the most intact tissue to repair
• Benefits observed in PDE5i non-responders — men who don’t respond adequately to Viagra or Cialis
• Excellent safety profile across all trials — no serious adverse events attributable to treatment
• No systemic side effects — unlike oral medications that affect blood pressure and vision, F-ESWT is entirely local

On the guideline front, the European Association of Urology (EAU) currently recommends ESWT — alone or in combination with PDE5 inhibitors — for men with mild vasculogenic ED and for poor responders to PDE5i therapy. The American Urological Association (AUA) classifies it as investigational (Grade C) given the need for further large-scale US trials, though this classification reflects the research pipeline rather than a concern about safety or efficacy.

F-ESWT vs. Other ED Treatments

Who Is the Ideal Candidate for F-ESWT?

F-ESWT is most effective for men with mild-to-moderate vasculogenic erectile dysfunction — meaning the primary cause of their ED is reduced penile blood flow rather than purely psychological or hormonal factors. Ideal candidates include:

• Men with ED related to cardiovascular risk factors (hypertension, high cholesterol, diabetes, metabolic syndrome)
• Men who have not responded adequately to PDE5 inhibitors (Viagra, Cialis, Levitra)
• Men who want to avoid daily medication and its systemic side effects
• Men with early-stage ED who want to address the problem before it progresses
• Men who are not candidates for, or do not want, surgical intervention

A thorough consultation — including medical history, current medications, and vascular health assessment — will determine whether F-ESWT is appropriate for your specific case.

What to Expect During Treatment

F-ESWT sessions at City Interventional Radiology are performed in-office with no anesthesia required. A typical treatment protocol involves:

• Session duration: Approximately 20–30 minutes per visit
• Number of sessions: Typically 6–12 sessions depending on severity and response
• Frequency: Usually 1–2 sessions per week
• Comfort level: Most patients describe a mild tingling or tapping sensation — not painful
• Downtime: None — return to normal activity immediately
• Results timeline: Improvement often begins within weeks; peak benefit typically at 3–6 months as neovascularization matures

Because the biological repair process takes time — new blood vessels don’t form overnight — patience is part of the protocol. The improvements that occur are the result of genuine tissue regeneration, which is why they tend to last well beyond the treatment period for appropriate candidates.

Frequently Asked Questions

City Interventional Radiology

Ready to Address the Root Cause of Your ED?

Our physicians specialize in vascular-based men’s health treatments, including F-ESWT. Schedule a confidential consultation to find out if focused shockwave therapy is right for you.

Schedule Your Consultation

No referral needed. Serving Manhattan, Huntington, Great Neck, and Nesconset.

The Bottom Line

Erectile dysfunction is not an inevitable consequence of aging, and it is not a condition men have to simply manage with daily pills for the rest of their lives. For the majority of men with vasculogenic ED, the underlying problem is a fixable one: insufficient blood flow caused by damaged or insufficient penile vasculature.

Focused Extracorporeal Shockwave Therapy (F-ESWT) is one of the only available treatments that works at the structural level — stimulating neovascularization, restoring nitric oxide signaling, and rebuilding the vascular infrastructure that erections depend on. With a strong safety profile, no systemic side effects, no downtime, and a growing body of randomized controlled trial evidence behind it, F-ESWT represents a meaningful advance in non-surgical ED care.

If you have been living with ED — whether newly diagnosed or struggling with inadequate response to medications — a consultation with the vascular medicine specialists at City Interventional Radiology is a concrete first step toward understanding your options and taking back control of your health.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Please consult a qualified healthcare provider to determine whether F-ESWT or any other treatment is appropriate for your individual condition.